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The Increased Expression of Matrix Metalloproteinase-9 
Messenger RNA in the Non-lesional Skin of Patients 
with Large Plaque Psoriasis Vulgaris
Sang Eun Lee, M.D., Wook Lew, M.D.
Department of Dermatology and the Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Background: A difference of the interleukin-18 (IL-18) mRNA 
expression among several proinflammatory genes was 
previously observed between large plaque (LP) psoriasis 
patients (more than 5 cm lesions are typical) and small 
plaque (SP) psoriasis patients (1∼2 cm lesions are typical). 
Therefore, it is necessary to test whether there is any 
difference in the expression of the genes that activate IL-18 
or the expression of genes that are induced by IL-18. 
Objective: To test the differential mRNA expressions of 
caspase-1, STAT-6, MMP-1, MMP-2, MMP-9 and TIMP-1 
according to the clinical types of psoriasis vulgaris lesions in 
Korean patients, we have analyzed the skin samples of 
psoriasis vulgaris patients. Methods: The total cellular RNA 
of skin samples from groups of patient with LP and SP 
psoriasis was analyzed by performing real-time PCR (the 
Taqman method) to compare the differences in the mRNA 
expressions. Results: The caspase-1 and STAT-6 mRNA 
expression levels from the SP lesional skin of the patients 
were increased compared with the caspase-1 and STAT-6 
mRNA expression levels from SP non-lesional skin or normal 
skin, but these expression levels from the SP non-lesional 
skin were not significantly different from those of the LP 
non-lesional skin. Among MMP-1, MMP-2, MMP-9 and 
TIMP-1, the expressions of MMP-1, MMP-2 and MMP-9 
mRNA were increased in the SP lesional skin compared with 
those of the SP non-lesional skin. The MMP-1 mRNA 
expressions in both the LP and SP lesional skin were in-
creased compared with those in the normal skin (p=0.028 
and p=0.007 respectively). The MMP-9 mRNA expression 
in the LP non-lesional skin was elevated compared with the 
MMP-9 mRNA expression in the SP non-lesional skin 
(p=0.047). The TIMP-1 mRNA expression levels from the 
non-lesional skin and the lesional skin of the psoriasis 
patients and the normal skin samples were not significantly 
different. Conclusion: The increased expression of MMP-9 
mRNA in the LP non-lesional skin compared to that of the SP 
non-lesional skin in the psoriatic skin suggests that the 
increased MMP-9 mRNA expression is related to the large size 
type of lesion. (Ann Dermatol (Seoul) 21(1) 27∼34, 2009)
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INTRODUCTION
Psoriasis is a chronic inflammatory dermatosis that is 
characterized by epidermal hyperplasia, angiogenesis and 
chronic inflammatory infiltrates, and the latter are com-
posed of activated type 1 T cells, dendritic cells and 
neutrophils1-5. Several gene expression studies have sug-
gested a coordinated activation of the type 1 inflammatory 
axis in the skin lesions of patients with psoriasis vulgaris 
along with an increased production of interferon (IFN)-γ- 
inducing inflammatory mediators/chemokines that sustain 
the chronic influx of leukocytes6-8. Among the several 
proinflammatory genes (IFN-γ, interleukin [IL]-12/23 p40, 
IL-18, IL-8, monocyte chemoattractant protein-1 [MCP-1], 
macrophage inflammatory protein-3α [MIP-3α], IFN-γ- 
inducible protein of 10 kDa [IP-10], IFN-inducible T-cell 
a-chemoattractant [I-TAC], monokine induced by IFN-γ 
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[MIG] and inducible nitric oxide synthase [iNOS], S100A2), 
only a difference in the IL-18 mRNA expression was 
previously observed between Western large plaque (LP) 
psoriasis patients (more than 5 cm lesions are typical) and 
Asian small plaque (SP) psoriasis patients (1∼2 cm lesions 
are typical)9. Therefore, it is necessary to determine 
whether there is any difference in the expression of the 
genes that activate IL-18 or if those genes are induced by 
IL-18. Among these genes, caspase-1 was selected due to 
its enzymatic activation of IL-18, and matrix metallopro-
teinase (MMP)-9 and MMP-2 were also selected as they 
are known to be induced by IL-18 and tissue inhibitor of 
matrix metalloproteinase-1 (TIMP-1) was selected due to 
MMP-9 specific activity10-12. In addition to these genes, 
MMP-1, which is known to be induced by IFN-γ13, and 
signal transducer and activator of transcription-6 (STAT-6), 
which is known to be a signal transducer of the type 2 
response, were selected for comparison14.
MATERIALS AND METHODS
Study design and the patients' entry criteria
Skin samples were collected from the non-lesional skin 
and the lesional plaques of LP and SP psoriasis patients 
and the skin of healthy volunteers (4 patients and 4 
normal controls in each group) by performing incisional 
biopsy. If at least one lesion was ≥5 cm, then the patient 
was classified into the LP type. If all the lesions on a 
patient were ＜5 cm, then the patient was classified into 
the SP type. Four patients with moderate-to-severe LP 
psoriasis (＞10% of the body surface area was affected) 
and 4 patients with SP psoriasis (＜20% of the body 
surface area was affected) were selected. All the patients 
in this study were Koreans. An incisional biopsy was taken 
from both the involved skin and the uninvolved skin 
adjacent to the lesions. The biopsies were divided in half 
at 1 mm toward the non-lesional side of the border for 
RNA preparation of the lesional skin and the uninvolved 
skin. All the specimens were kept in liquid nitrogen until 
needed. A diagnosis of psoriasis was confirmed for all the 
patients by histopathology. The age at onset was 6∼25 
years old (mean: 16.8 years) for the LP psoriasis patients 
and 16∼43 years old (mean: 28.5 years) for the SP 
psoriasis patients. One of the LP psoriasis patients had a 
family history of psoriasis, but the SP psoriasis patients 
had no family history of psoriasis. The duration of ex-
acerbation was 1∼24 months (mean: 15.3 months) for the 
four LP psoriasis patients and this was 0.5∼1 months 
(mean: 0.75 months) for 2 of the SP psoriasis patients. 
However, one case of SP psoriasis did not exacerbate, 
instead, the repeated appearance and disappearance of 
the different plaques persisted for 4 years. The LP psoriasis 
plaque that was biopsied from the periphery of the plaque 
was a stable plaque of at least 1 month duration. 
However, the SP psoriasis plaque that was biopsied was a 
recent stable plaque of at least 0.5∼1 months duration, 
including the middle of the plaque and the periphery, 
because the plaque size taken from the SP psoriasis by a 
1.5∼2 cm-sized incisional biopsy was usually less than 2 
cm in diameter. The clinical course of psoriasis for both 
the LP and SP types was similar except for the severity of 
the disease. The LP psoriasis patients had been previously 
treated prior to this study with UVB or PUVA photo-
therapy or other systemic therapy in addition to topical 
steroid therapy. The LP psoriasis patients were off systemic 
therapies for at least 1 month and they were off topical 
therapies for at least one month prior to biopsy. The SP 
psoriasis patients were treated with topical steroids prior 
to the biopsy, but they were off topical steroids for at least 
one month prior to the biopsy. However, the microscopic 
findings of the biopsy specimens of both the LP and SP 
psoriasis patients were typical psoriasis, according to the 
histopathology. Biopsy specimens of the surrounding 
normal skin, after removing any benign tumors, were 
obtained from 4 healthy volunteers. The study protocol 
was approved by the Institutional Review Board of 
Youngdong Severance Hospital, Yonsei University College 
of Medicine, Seoul, Korea, and informed consent was 
obtained from each patient.
Quantitative reverse transcription polymerase chain 
reaction
The total cellular RNA was prepared from the frozen 
specimens using a rotor-stator PowerGen 700 (Fisher 
Scientific, Pittsburgh, PA, USA) and the RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to the manu-
facturer's protocol. The RNA was treated directly in the 
column with 27 units of RNase-Free DNase I (Qiagen, 
Valencia, CA, USA) for 15 minutes at room temperature 
during the extraction procedure. The RNA was eluted by 
diethylpyrocarbonate-treated (DEPC-treated) sterile water, 
and the RNA concentration was determined by measuring 
the optical absorbance at 260 nm. Then, rTth DNA Poly-
merase was used to reverse transcribe and amplify 5 ng of 
the total RNA in a single tube assay with using the Perkin 
Elmer TaqMan EZ RT-PCR kit (Perkin Elmer Applied 
Biosystems, Foster City, CA, USA) and with using gene- 
specific sense and antisense primers and a probe flu-
orescently labeled at the 5' end with 6-carboxy-fluorescein 
(6-FAM)15,16. Caspase-1, STAT-6, MMP-1, MMP-2, MMP-9 
and TIMP-1 assay-on-demand primers and a fluorescently 
labeled probe set were purchased from Perkin Elmer-ABI. 
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Fig. 1. (A) The caspase-1 mRNA and (B) STAT-6 mRNA expressions in psoriatic lesions. The total cellular RNA was prepared from 
the non-lesional and lesional skin of four patients with large plaque (LP) psoriasis, and from the non-lesional and lesional skin of 
four patients with small plaque (SP) psoriasis. The mRNA was amplified for the indicated genes by performing quantitative reverse 
transcription-polymerase chain reaction. The levels of RNA were normalized to human acidic ribosomal protein. The mean±SD 
expression levels in the non-lesional and lesional skin are presented for all four patients. *Statistically significant differences (p＜0.05)
between the non-lesional and lesional skin (or the normal control and lesional skin) of the patients with the SP type of psoriasis.
**Statistically significant differences (p＜0.05) between the normal control and lesional skin of patients with the SP type of psoriasis.
Empty box: normal volunteer skin, dotted box: non-lesional skin of LP psoriasis, striped box: lesion of LP psoriasis, shaded box: 
non-lesional skin of SP psoriasis, filled box: lesion of SP psoriasis.
The gene for human acidic ribosomal protein (hARP), 
which is a constitutively expressed housekeeping gene, 
and the primers and fluorescently labeled probe were 
generated using Primer Express software version 1.5 
(Perkin Elmer-ABI) and they were synthesized by a Perkin 
Elmer-ABI. To avoid amplification of any contaminating 
genomic DNA, primer pairs were selected that crossed the 
intron/exon borders whenever possible. Duplicate sam-
ples were reverse transcribed and then amplified: 2 min at 
50oC, 30 minutes at 60oC and then 40 rounds of ampli-
fication for 15 seconds at 95oC and 1 minute at 60oC with 
using the ABI Prism 7700 sequence detection system as 
described by the manufacturer (Perkin Elmer-ABI)15. Se-
quence-specific amplification was detected as an in-
creased fluorescent signal of 6-FAM during the ampli-
fication cycle. Quantitation of the gene-specific message 
levels was based on a comparison of the fluorescence 
intensity in the unknown total RNA sample to the 
fluorescent intensity from a standard curve of the control 
mRNA levels. Amplification of the gene for hARP was 
performed on all the samples tested to control for 
variations in the amounts of RNA17. All the genes were 
subsequently normalized against the hARP mRNA levels. 
The levels of the gene-specific messages were graphed as 
normalized message units as determined from the stan-
dard curve.
Statistical analysis
The quantitative measures of the changes of gene ex-
pression were statistically evaluated. Differences between 
the paired sites were analyzed using 2-tailed paired t test 
comparisons. For all the comparisons, a p value less than 
0.05 was used to indicate statistical significance.
RESULTS
The expression of caspase-1 and STAT-6 mRNA
The caspase-1 mRNA expression in the lesional skin of the 
LP and SP psoriasis patients was increased by 1.47-fold 
and 1.79-fold, respectively, as compared with that of the 
non-lesional skin, but only the SP lesional skin showed a 
significant increase (p=0.028). The caspase-1 mRNA 
expression in the LP non-lesional and lesional skin was 
increased by 1.06-fold and 1.57-fold, respectively, as 
compared with that of the normal skin, and the differences 
were not significant. The caspase-1 mRNA expression in 
the SP non-lesional skin was slightly decreased by 
0.95-fold, while the caspase-1 mRNA expression in the SP 
lesional skin was significantly increased by 1.71-fold 
(p=0.025), as compared with that of the normal skin (Fig. 
1A).
The STAT-6 mRNA expression in the LP lesional skin was 
slightly decreased in comparison with that of the LP 
non-lesional skin (a 0.8-fold decrease), while in SP 
lesional skin, the STAT-6 mRNA expression was slightly 
increased in comparison with that of the SP non-lesional 
skin (a 1.12-fold elevation), but the differences were not 
significant. Compared with the STAT-6 mRNA expression 
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Fig. 2. (A) The MMP-1, (B) MMP-2, (C) MMP-9 and (D) TIMP-1 mRNA expressions in psoriatic lesions. The total cellular RNA was 
prepared from the non-lesional skin and lesional skin of four patients with large plaque (LP) psoriasis, and from the non-lesional 
skin and lesional skin of four patients with small plaque (SP) psoriasis. The mRNA was amplified for the indicated genes by performing
quantitative reverse transcription-polymerase chain reaction. The levels of RNA were normalized to human acidic ribosomal protein.
The mean±SD expression levels in the non-lesional skin and lesional skin are presented for all four patients. *Statistically significant
differences (p＜0.05) between the non-lesional skin and lesional skin (or normal control and lesional skin) of the patients with the 
SP type of psoriasis; **statistically significant difference (p＜0.05) between the normal control skin and the lesional skin of patients 
with the LP type of psoriasis; ***statistically significant differences (p＜0.05) between the non-lesional skin and the lesional skin 
of patients with the SP type of psoriasis; ****statistically significant difference (p＜0.05) between the non-lesional skin of the LP
type and the non-lesional skin of the SP type; empty box: normal volunteer skin, dotted box: non-lesional skin of LP psoriasis, striped
box: lesion of LP psoriasis, shaded box: non-lesional skin of SP psoriasis, filled box: lesion of SP psoriasis.
in normal skin, the STAT-6 mRNA expression was 
increased in the LP non-lesional skin (by 2-fold), in the LP 
lesional skin (by 1.61-fold), in the SP non-lesional skin (by 
1.29-fold) and in the SP lesional skin (by 1.46-fold), and 
among these only the SP lesional skin showed a 
significant increase (p=0.045) (Fig. 1B). 
The expression of MMP-1, MMP-2, MMP-9 and TIMP-1 
mRNA
The MMP-1 mRNA expression in the LP lesional skin was 
slightly decreased by 0.67-fold compared with that of the 
LP non-lesional skin, but it was significantly increased in 
the SP lesional skin by 6.04-fold compared with that of the 
SP non-lesional skin (p=0.037). However, the MMP-1 
mRNA expression in the LP non-lesional skin was in-
creased by 9.44-fold compared with that of the SP 
non-lesional skin, but the difference was without signi-
ficance. Compared with that in the normal skin, the 
MMP-1 mRNA expression in the LP non-lesional and 
lesional skin was increased by 60.49-fold and 40.31-fold, 
respectively, and among them only the LP lesional skin 
showed a statistically significant increase (p=0.028) and 
the MMP-1 mRNA expression in the SP non-lesional and 
lesional skin was increased by 6.41-fold and 38.74-fold, 
respectively, and among them only the SP lesional skin 
showed a statistically significant increase (p=0.007) (Fig. 
2A).
The MMP-2 mRNA expression in the LP lesional skin was 
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Table 1. Changes in matrix metalloproteinases and tissue inhibi-
tors of metalloproteinases in psoriatic lesions
MMP/TIMP Effect Reference
MMP-2 ＋ [23]
MMP-3 ＋* [24]
MMP-9 ＋ [23,24]
MMP-11 − [25]
MMP-12 ＋ [24]
MMP-19 ＋ [26]
MMP-28 − [26]
TIMP-1 ＋ [24]
TIMP-3 ＋ [24]
MMP: matrix metalloproteinase, TIMP: tissue inhibitors of me-
talloproteinase, ＋: increase, −: no expression, *: only expressed 
in some cases
slightly increased by 1.45-fold compared with that of the 
LP non-lesional skin, but the expression in the SP lesions 
was significantly increased by 1.81-fold compared with 
that of the SP non-lesional skin (p=0.029). The MMP-2 
mRNA expression in the LP non-lesional skin was de-
creased by 0.83-fold compared with that of the SP 
non-lesional skin, and the difference was not significant. 
Compared with that in the normal skin, the MMP-2 mRNA 
expression was decreased in the LP non-lesional skin by 
0.83-fold, and it was increased in the LP lesion by 
1.21-fold, it was nearly the same in the SP non-lesional 
skin (a 1.01-fold increase) and it was increased in the SP 
lesion by 1.82-fold; however, all of these differences were 
not significant (Fig. 2B). Therefore, the elevation of the 
MMP-2 mRNA level in the lesion compared with the 
non-lesional skin is probably more significant in the SP 
type of psoriasis than that in the LP type of psoriasis.
The MMP-9 mRNA expression in the LP lesional skin was 
slightly decreased by 0.69-fold compared with that of the 
LP non-lesional skin, whereas the MMP-9 mRNA expres-
sion in the SP lesional skin was significantly increased by 
3.21-fold compared with that of the SP non-lesional skin 
(p=0.031). Compared with that of the SP non-lesional 
skin, the LP non-lesional skin showed a significantly 
increased MMP-9 mRNA expression level by 3.25-fold 
(p=0.047). Compared with that of normal skin, the 
MMP-9 mRNA expression was increased in the LP 
non-lesional skin by 1.32-fold, it was decreased in the LP 
lesional skin by 0.92-fold, it was decreased in the SP 
non-lesional skin by 0.4-fold and it was increased in the 
SP lesional skin by 1.31-fold, yet all of these differences 
were not significant (Fig. 2C).
The TIMP-1 mRNA expression in the LP and SP lesional 
skin was slightly decreased by 0.9-fold and 0.78-fold, 
respectively, compared with that of the LP and SP non- 
lesional skin, and the differences were not significant. 
Compared with that of normal skin, the TIMP-1 mRNA 
expression was increased in the LP non-lesional skin by 
1.72-fold, it was increased in the LP lesional skin by 
1.56-fold, it was increased in the SP non-lesional skin by 
1.63-fold and it was increased in the SP lesional skin by 
1.25-fold, however, all of these differences were not 
significant (Fig. 2D). Therefore, we did not observe any 
difference in the TIMP-1 mRNA expression between the 
two clinical types of psoriasis vulgaris.
DISCUSSION
The differential expression of IL-18 mRNA in the psoriatic 
lesions between SP psoriasis (typical Asian psoriasis) and 
LP psoriasis (typical Western psoriasis) has previously 
been reported9. Since then, we have analyzed and found 
that a similar difference in the IL-18 mRNA expression 
was also observed between SP and LP psoriasis patients 
who have the same Asian ethnic background (data not 
shown).
When we analyzed the caspase-1 mRNA expression level 
between LP and SP psoriasis to indirectly determine the 
difference in the activity of IL-18, we could observe that 
the caspase-1 mRNA expression was significantly in-
creased in the lesional skin compared with non-lesional 
skin and the normal skin in only SP psoriasis patients, 
suggesting that the increased expression of caspase-1 
mRNA in the SP lesional skin may be more related to the 
activation of IL-18 (Fig. 1A). In case of the level of the 
STAT-6 mRNA expression between LP and SP psoriasis, 
the expression levels were not different between them. 
There was only a significant elevation of the STAT-6 
mRNA level in the SP lesional skin compared with the 
level in the normal skin (Fig. 1B), and this implicated that 
the function of Th2 cytokines may be more prominent in 
the SP lesional skin compared with that of normal skin, 
which is presumably due to the response to inflammation 
since STAT-6 is known to be increased by the activation of 
Th2 cytokines like IL-4 or IL-10.
Cytokines have long been known to induce MMPs10-13,18-21. 
However MMPs can also influence certain cytokine ac-
tivities22. Therefore, the counter regulation of MMPs and 
cytokines seems to be important for both activities. 
Several MMPs were previously reported to be elevated in 
psoriatic lesions (Table 1)23-26. The IFN-α produced by 
plasmacytoid predendritic cells was recently demonstrated 
to be an important initiator in the development of 
psoriasis27,28. An MMP-1 expression has been reported to 
be induced by IFN-α29 which has been shown to be 
involved in the early development of psoriasis in a ARG-/- 
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xenograft model27. Thus, the expression level of MMP-1 
mRNA is predicted to have some role in the early 
development of psoriasis. In our study, the MMP-1 mRNA 
expression level in the LP non-lesional skin was not 
significantly different from the MMP-1 mRNA expression 
level in the SP non-lesional skin, although the MMP-1 
mRNA expression levels in both LP lesional skin and SP 
lesional skin were elevated compared to the MMP-1 
mRNA expression level in normal skin. Therefore, the 
elevation of the MMP-1 mRNA expression in the lesional 
skin is thought to be the secondary response to the 
inflammatory cytokines that are produced in psoriasis 
lesions. However, Flisiak et al30,31 reported that the 
elevated levels of MMP-1 and TIMP-1 in psoriatic plasma 
and the levels of MMP-1 and TIMP-1 in psoriatic plasma 
were inversely correlated to the disease severity (a 
decrease in MMP-1 and an increase in TIMP-1). The level 
of MMP-1 in psoriatic scales was also shown to be 
inversely correlated to the psoriasis severity30. Although 
MMP-2 was shown to be overexpressed in the psoriatic 
lesions23,32, we could only observe the significant eleva-
tion of the MMP-2 mRNA level in the lesions of SP 
psoriasis (and not in LP psoriasis), as compared with the 
MMP-2 mRNA level in the non-lesional skin. This 
elevation is thought to be due to a secondary inflam-
matory response. MMP-9 can be induced by cytokines 
such as TNF-α and IFN-γ, which are known to be 
upregulated in psoriasis33-38. The MMP-9 mRNA expres-
sion level in the LP non-lesional skin was elevated 
compared with that in the SP non-lesional skin, indicating 
that there is a difference in the MMP-9 mRNA expression 
between the two clinical types of psoriasis. This tendency 
of the MMP-9 suggests that the elevation of the MMP-9 
mRNA expression in the non-lesional skin of psoriasis 
vulgaris is related to the large size type of lesion. 
However, there was no significant difference in the 
expression of TIMP-1, which is a specific inhibitor of 
MMP-9, between the non-lesions of the two types of 
psoriasis. Although several MMPs are known to be 
elevated in psoriasis, these elevations have also been re-
ported to be associated with other skin disorders25,39,40. In 
lichen planus, the digestion of the basement membrane by 
MMP-2 may contribute to the pathogenesis by inducing 
an altered integrin expression in basal keratinocytes and 
ultimately blister formation39. MMP-11 (stromelysin-3) 
seems to be associated with benign fibroblastic tumors25. 
Increased expressions of MMP-2, MMP-9 and MMP-13 
were demonstrated in the lesional skin of patients suf-
fering with bullous pemphigoid40. However, these changes 
in the MMPs seem to be due to a secondary phenomenon 
of inflammation or tumorigenesis. A recent study on 
anti-TNF-α therapy in psoriasis patients suggested that the 
clinical improvement correlated more with the level of 
MMP-9 than with the level of MMP-2 in the lesions41,42. 
Therefore, the increased expression of MMP-9 in the 
non-lesional skin of LP psoriasis patients is thought to be 
more relevant to the pathogenesis of psoriasis than with 
the expression of other MMPs. An increased expression of 
MMP-9 during the progression of carcinogenesis, and 
decreased tumor metastasis in MMP-9-deficient mice have 
been reported43,44. These findings suggested that MMP-9 is 
a crucial factor for the progression of carcinogenesis and 
metastasis. Therefore, further study is necessary to elucidate 
whether MMP-9 is a factor that governs the expansion of 
the lesions in psoriasis patients.
In summary, among the mRNA expression levels of 
caspase-1, STAT-6, MMP-1, MMP-2, MMP-9 and TIMP-1 
mRNA, the expressions of caspase-1, MMP-1, MMP-2 and 
MMP-9 mRNA were increased in the SP lesional skin 
compared with that of the SP non-lesional skin (the 
STAT-6 mRNA in the SP lesional skin was increased 
compared with that of normal skin). The level of the 
MMP-9 expression from the LP non-lesional skin was 
significantly increased compared with the MMP-9 level in 
the SP non-lesional skin, suggesting that the increased 
level of the MMP-9 mRNA expression in the non-lesional 
skin of psoriasis vulgaris patients is related to the large 
size type of lesion. Further study is necessary to discover 
the meaning of the differential expression of these genes 
in patients suffering with SP and LP psoriasis.
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